文献速递艾滋病与性传播感染病毒性肝炎

HIV-HBV共感染中乙型肝炎核心相关抗原与抗-HBc抗体动力学及其与血清学应答的关联

Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection.
PubMed 文献 · J Infect Dis · 2020-01-01

本研究在HIV-HBV共感染患者接受替诺福韦治疗期间,描述量化乙型肝炎核心相关抗原(qHBcrAg)和量化抗-HBc抗体(qAnti-HBc)的动力学,并评估其预测HBeAg血清清除的能力。结果显示,在HBeAg阳性患者中,基线qHBcrAg和qAnti-HBc水平与HBeAg血清清除相关,特定界值对36个月HBeAg血清清除具有预测价值。

要点

  • qHBcrAg在HBeAg阳性患者中呈双相下降,在HBeAg阴性患者中呈单相下降。
  • 基线qHBcrAg和qAnti-HBc水平与HBeAg血清清除独立相关。
  • 第24个月qHBcrAg <6.5 log10 U/mL预测36个月HBeAg血清清除的敏感性为1,特异性为0.58。

核心结论

  • 在HIV-HBV共感染接受TDF治疗的患者中,qHBcrAg和qAnti-HBc可用于监测HBeAg血清清除。

研究设计与样本

  • 研究纳入158例HIV-HBV共感染患者,在TDF起始及每6-12个月检测血清qHBcrAg、qAnti-HBc和HBV DNA。
  • 采用混合效应线性回归估计qHBcrAg和qAnti-HBc的治疗中动力学,采用比例风险回归计算风险比,采用时间依赖ROC曲线评估预测准确性。

主要发现

  • 中位随访4.6年,HBsAg和HBeAg累积清除率分别为3.2%(5/158)和27.4%(26/95)。
  • HBeAg阳性患者中ΔqHBcrAg呈双相(≤18个月为-0.051 log10 U/mL/月,>18个月为-0.011 log10 U/mL/月),HBeAg阴性患者呈单相;ΔqAnti-HBc在所有患者中呈单相。
  • 预测36个月HBeAg血清清除的最佳界值:第24个月qHBcrAg <6.5 log10 U/mL(敏感性1,特异性0.58);基线qAnti-HBc ≥4.1 log10 PEI U/mL(敏感性0.42,特异性0.81)。

关键数值与推荐

  • 第24个月qHBcrAg <6.5 log10 U/mL预测36个月HBeAg血清清除的敏感性为1,特异性为0.58。
  • 基线qAnti-HBc ≥4.1 log10 PEI U/mL预测36个月HBeAg血清清除的敏感性为0.42,特异性为0.81。

临床怎么用

  • 在HIV-HBV共感染患者接受TDF治疗时,可考虑监测qHBcrAg和qAnti-HBc以辅助预测HBeAg血清清除。
  • 第24个月qHBcrAg <6.5 log10 U/mL或基线qAnti-HBc ≥4.1 log10 PEI U/mL提示更高的HBeAg血清清除可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of the current study was to describe the kinetics of quantified hepatitis B core-related antigen (qHBcrAg) and quantified anti-hepatitis B core antibody (qAnti-HBc) during tenofovir (TDF) treatment and assess their ability to predict hepatitis B e antigen (HBeAg) seroclearance in patients coinfected with human immunodeficiency virus (HIV) and hepatitis B virus. METHODS: Serum qHBcrAg, qAnti-HBc, and hepatitis B virus DNA were obtained at TDF initiation and every 6-12 months. The on-treatment kinetics of qHBcrAg (ΔqHBcrAg) and qAnti-HBc (ΔqAnti-HBc) were estimated using mixed-effect linear regression. Hazard ratios (HRs) assessing the association between markers and HBeAg seroclearance were calculated using proportional hazards regression, and the sensitivity (Se) and specificity (Sp) of marker levels in predicting HBeAg seroclearance were assessed using time-dependent receiving operating characteristic curves. RESULTS: During a median of 4.6 years, the cumulative incidences of hepatitis B surface antigen and HBeAg seroclearance were 3.2% (n = 5 of 158) and 27.4% (n = 26 of 95), respectively. ΔqHBcrAg was biphasic in HBeAg-positive patients (-0.051 and -0.011 log10 U/mL/mo during ≤18 and >18 months, respectively) and monophasic in HBeAg-negative patients. ΔqAnti-HBc was monophasic regardless of HBeAg status. In HBeAg-positive patients, baseline qHBcrAg and qAnti-HBc levels were associated with HBeAg seroclearance (adjusted HR, 0.48/log10 U/mL [95% confidence interval, .33-.70] and unadjusted HR, 1.49/log10 Paul Ehrlich Institute units/mL [1.08-2.07], respectively). Cutoffs with the highest accuracy in predicting HBeAg seroclearance at 36 months were qHBcrAg <6.5 log10 U/mL at month 24 (Se, 1; Sp, 0.58) and baseline qAnti-HBc ≥4.1 log10 Paul Ehrlich Institute units/mL (Se, 0.42; Sp, 0.81). CONCLUSIONS: In coinfected patients undergoing TDF, qHBcrAg/qAnti-HBc could be of use in monitoring HBeAg seroclearance.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dezanet LNC, Maylin S, Gabassi A, et al. Kinetics of Hepatitis B Core-Related Antigen and Anti-Hepatitis B Core Antibody and Their Association With Serological Response in Human Immunodeficiency Virus-Hepatitis B Coinfection. J Infect Dis. 2020. PMID: 31960918. doi:10.1093/infdis/jiaa013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。